Bio + Health

Investing in Ease

Daisy Wolf, Anish Acharya, and Eva Steinman Posted March 2, 2026

Today, one in five Americans receive behavioral health services. As that number has grown over the last decade, reimbursement for these services has expanded accordingly. But amid this growth, the industry’s core infrastructure has lagged behind. The software that powers scheduling, documentation, billing, and care coordination remains stuck in the past. The result is a paradox: a sector flooded with patient demand, but starved of the necessary underlying tools to meet this demand effectively. We believe that the company that solves this will build one of the most important platforms in all of healthcare.

Behavioral health sits at the center of healthcare’s cost and access challenges: demand continues to rise, reimbursement is a tangled web, and the software supporting clinicians was built for an earlier era of healthcare. To compensate, providers have assembled patchwork technology stacks: a legacy EHR for documentation, a separate tool for intake and eligibility, another system for revenue cycle, and a complicated web of workarounds to hold the fragile pieces together. Even within their narrow scope, current tools fall short; they function in isolation, compounding errors rather than enabling a unified workflow. This fragmentation drives higher software spend and serious operational overhead—from delayed access to care to lost revenue opportunities and clinician burnout.

Historically, incentives in behavioral health software have been misaligned. Companies optimized for short-term cash flow rather than long-term product quality, and practices became increasingly burdened by their vendors’ ever-growing technical debt. EHRs were largely single-function systems that didn’t capture enough wallet share to support venture-scale outcomes. The result was a prolonged period of underinvestment, with limited innovation and venture capital largely on the sidelines.

That era is over. We could not be more thrilled to lead Ease’s $41M Series A to redefine healthcare’s operating system, unifying intake (CRM), clinical (EHR), and billing (RCM) into a single, AI-native core platform.

Ease unifies admissions, care, and billing into a single platform designed to eliminate administrative burden and become the provider’s core system. EHRs have long sat at the center of care delivery, but they were designed to digitize paper records, not to run modern organizations. (Just ask any provider about their EHR’s NPS!) Ease transforms the EHR from a compliance obligation into a growth engine—improving clinician efficiency, and consolidating software spend onto a single platform. Built on a unified data model, Ease’s AI supports the entire practice team, from administrators and billers to providers and executive leadership teams. Since launching, the Ease team has rapidly built a vertically integrated AI stack for their customers, spanning ambient documentation, automated charting and chart auditing, a CRM and agentic call center, and an autonomous prior authorization engine, among other hugely important elements of physician workflows. Their strategy is to create a unified intelligence layer: once data enters the system, Ease’s AI orchestrates workflows end-to-end, propagating context across clinical records, forms, and operational processes to drive efficiency, accuracy, and leverage at scale.

We’ve seen this playbook succeed in other industries. Companies like Toast, Rippling, Stripe, and ServiceTitan each built category-defining businesses by consolidating fragmented workflows into a single unified operating system, leveraging technology, data, and distribution to displace point solutions. Behavioral health is ripe for the next transformation, and Ease’s team is perfectly positioned to scale its core technology engine across other ambulatory markets that are long overdue for reinvention.

Ease is already live and scaling with customers, and we’ve been deeply impressed by the product, team and speed of execution. The founding team brings deep experience across healthcare, technology, and company building. CEO Zach Cohen is a former investing partner at a16z. CTO Raymond Wang is an engineering leader with a track record of building and scaling elite technical teams. President Steve Gold previously built and sold the behavioral health leader Refresh to Optum. Together, they bring an unusual combination of operator depth and domain expertise to one of healthcare’s most structurally important challenges.

We can’t wait to support Zach, Raymond, and Steve as they build the infrastructure for the next generation of care.

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Infra

new Investing in Deeptune

Marco Mascorro and Martin Casado
Growth

new Investing in Mind Robotics

Sarah Wang
Growth

Investing in Nexthop AI

Raghu Raghuram, Shangda Xu, and Guido Appenzeller
Fintech

Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts
Infra

Investing in QuiverAI

Yoko Li, Guido Appenzeller, and Martin Casado

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.